Centessa Pharmaceuticals plc
NasdaqGS:CNTA Stok Raporu
Centessa Pharmaceuticals Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6 Centessa Pharmaceuticals şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler Toplam Hissedar Getirisi -6.5% Gelecekteki Temettü Verimi n/a Temettü Büyümesi n/a Bir sonraki temettü ödeme tarihi n/a Eski temettü tarihi n/a Hisse başına temettü n/a Ödeme oranı n/a
Son temettü ve geri alım güncellemeleri
Tüm güncellemeleri göster
CEO & Director recently sold US$864k worth of stock Oct 25
CEO & Director notifies of intention to sell stock Oct 24
Chief Business Officer recently sold US$261k worth of stock Sep 29
Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B Sep 25
CEO & Director notifies of intention to sell stock Sep 23 Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million. Sep 12
Chief Business Officer notifies of intention to sell stock Sep 11
Price target increased by 10% to US$16.00 Sep 10
Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers Sep 10
CEO & Director notifies of intention to sell stock Aug 26
Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry? Aug 15
Price target increased by 9.2% to US$14.20 Jun 21 Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes
Insufficient new directors Jun 02 Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.
Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million. Apr 24
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point Apr 24 Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million. Apr 24
Centessa Pharmaceuticals plc Announces Open IND for ORX750 Apr 23
Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt? Mar 07
New major risk - Revenue and earnings growth Mar 05
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia Dec 11
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors Nov 01
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders Oct 26
Insider notifies of intention to sell stock Sep 22
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc Aug 25
New major risk - Revenue and earnings growth Aug 14
Price target increased by 18% to US$7.08 Jul 25
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors Jul 12
New minor risk - Share price stability Jul 06
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B May 23
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors Jan 27
Centessa Pharmaceuticals plc Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia Dec 13
Centessa Pharmaceuticals Announces Karen Anderson as New Chief People Officer Dec 01
Price target decreased to US$6.00 Nov 16
High number of new and inexperienced directors Nov 16
The Law Offices of Vincent Wong Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc Nov 15
Centessa Pharmaceuticals snaps multi-day losing streak; up 10% Oct 20
Centessa Pharmaceuticals plc Announces Departure of Javad Shahidi as Chief Medical Officer Oct 15
Centessa Pharmaceuticals plc Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc Sep 30
Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status Sep 14
Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index Sep 13
Centessa Pharmaceuticals GAAP EPS of -$0.69 Aug 10
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, Phd, as Senior Vice President of Regulatory Affairs Jul 26
Centessa Pharmaceuticals plc Announces Executive Changes Jul 09
Centessa Pharmaceuticals plc Announces Board Changes Jul 02
Centessa Pharmaceuticals plc Announces Poster Presentation of First Preclinical Data for LockBody Program At 2022 ASCO Annual Meeting Jun 06
Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Jun 03
Centessa Pharmaceuticals plc, Annual General Meeting, Jun 30, 2022 May 24
High number of new and inexperienced directors Apr 27
High number of new and inexperienced directors Apr 05
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 Action Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease Feb 25
Centessa Pharmaceuticals Limited Announces Resignation of Robert M. Califf as Member of the Board of Directors Feb 17
Checking In On Centessa Pharmaceuticals Dec 23
Centessa Pharmaceuticals plc Together with Subsidiary Palladio Biosciences, Inc. Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease and Reports Initial Positive Safety Data from ALERT Study Dec 15
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis Sep 10
Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high Jun 14
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: CNTA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: CNTA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi Centessa Pharmaceuticals Piyasaya Karşı Temettü Getirisi
CNTA temettü verimi piyasa ile karşılaştırıldığında nasıldır? Segment Temettü Verimi Şirket (CNTA) n/a Pazarın Alt %25'i (US) 1.3% Pazarın En İyi %25'i (US) 4.3% Sektör Ortalaması (Biotechs) 2.1% Analist tahmini (CNTA) (3 yıla kadar) n/a
Önemli Temettü: CNTA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CNTA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: CNTA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranı nı hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: CNTA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
